undamentalytics Newsletter
Sign in

Gossamer Bio, Inc. revenue

Gossamer Bio, Inc.'s revenue was $48.5m in fiscal 2025, down 57.7% on the year before. Over the last twelve months it was $53.3m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue001154853
Growth on the year before———−57.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Revenue From Contracts With Collaborators $48.5M 100.0% ▲ 101.8%
Licenses and services $0 0.0% ▼ 100.0%

From Gossamer Bio, Inc.'s 10-K filed March 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Gossamer Bio, Inc. $53.3m 32.4% —
Siga Technologies Inc $53.7m -70.1% -18.1%
Tango Therapeutics, Inc. $53.8m 121.5% 16.9%
Ocular Therapeutix, Inc $52.1m -8.1% -1.6%
Nektar Therapeutics $54.6m -27.2% -14.6%
Invivyd, Inc. $58.4m 26.3% —

Compare with peers

Head to head: GOSS vs SIGAGOSS vs TNGXGOSS vs OCULGOSS vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Gossamer Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gossamer Bio, Inc.